BI 655130

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Dermatitis, AtopicHealthy

Phase 1

Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects

CompletedNCT03100903

Boehringer IngelheimHealthy

Start: 2017-04-24End: 2018-01-10Updated: 2025-10-16

Phase 2

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

CompletedNCT03822832

Boehringer IngelheimDermatitis, Atopic

Start: 2019-02-12End: 2020-07-22Updated: 2025-10-17

Related Papers

Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies

Clinical Pharmacokinetics2022-12-0110 citations